The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study
June 27, 2018
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
- Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- Nephrology Society to Issue New CKD Guidelines; Recommends Less-Strict Blood Pressure Management Target
June 4, 2018
- AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist
May 28, 2018
- Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass
May 21, 2018
- Dupixent Used Generally as Adjunctive Therapy to Existing Treatments for Atopic Dermatitis: Dermatologist
May 10, 2018
- 55 Anticancer Meds Available Overseas Unapproved in Japan, 3 Meds Costing over 10 Million Yen Monthly: NCC
May 2, 2018
- New Guidelines Recommend LAMA as First-Line Bronchodilator for COPD: Respiratory Society
April 24, 2018
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
- Expert Cautions against Hasty Discussions on Cost Effective Assessments
April 20, 2018
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President
April 19, 2018
- Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
- Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof.
April 2, 2018
- Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients
March 6, 2018
- Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
March 1, 2018
- LSI Medience, NCC, and NIBIOHN Team Up for National Project to Develop PDX Mice
February 26, 2018
- Major Drug Makers to Join in AMED Project to Develop “Organs on Chips” as New Tools for Drug Discovery
February 22, 2018
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…